Recent articles
Is Amarin Stock a Buy?
Record revenues, international growth, and a potential legal strategy may provide upside.
Is Exact Sciences Stock a Buy?
Q1 results were mixed, but the company’s strategy may be key for top-line growth ahead.
Is Catalyst Pharmaceuticals a Buy?
Several catalysts could drive this biopharma higher, but there are some significant risks ahead, too.
Your 2 Top Profit Opportunities in 2020
These two underrated biotech stocks have the potential to soar.
Is Exelixis a Buy?
Cheap and ready to outperform, this under-the-radar biotech stock could be a winner.
Is BioMarin Pharmaceutical Stock a Buy?
Is this a prime opportunity for investors to buy the gene therapy drugmaker?
This 1 Stock Is a Good Buy During the Coronavirus Sell-Off
Acadia Pharmaceuticals' track record of success and strong pipeline offers an attractive long-term opportunity for investors, especially at a depressed price.
Can Halozyme Therapeutics Continue Its Momentum in 2020?
The biopharma's strategic moves in 2019 may set the company up for long term growth.
Here's Why Clovis Oncology Has Upside Potential in 2020
The cancer-drug maker has a novel medicine that may provide growth opportunities in other areas of cancer.
Here's Why Karyopharm Therapeutics Has a Unique Growth Opportunity
This cancer-drug maker has a novel medicine with the possibility for extraordinary growth.
BioMarin's Novel Treatment Promises to Disrupt Competitors
The gene therapy maker's novel medicine has the potential to take over a highly competitive market and offer growth opportunities for investors.
The Growth Opportunity That Will Move Medtronic Ahead of Its Rivals
One key division offers strong demand and a solid long-term opportunity for investors.
Gilead Sciences Looks Ready to Outpace AbbVie
Which biopharmaceutical company is a better long-term value?
Storage Wars: Where Does Western Digital Stack Up Against Its Rivals?
Data storage giant Western Digital competes in a highly competitive space; does it still have a hot hand in the new decade?
Is It Time to Retreat on Qorvo?
The radio frequency chipmaker topped earnings expectations, but where is it headed?
Advanced Micro Devices: Has the Stock Reached Its Peak?
The chipmaker narrowly beat Q4 2019 earnings expectations, but uncertainty in 2020 could drive the stock lower.
Will Eli Lilly Outperform in 2020?
Recent progress in its drug pipeline and a focus on dealmaking offer strong value for shareholders.
This Cancer Drug Is Driving Forty Seven's Stock Higher
Positive data from a recent study on its lead compound signifies a turning point for the company and could provide further value for investors.
How Should Investors Approach Exact Sciences in 2020?
After a successful 2019, the diagnostics company faces new growth opportunities with both Cologuard and its cancer-diagnostics pipeline.
Can Investors Excel in 2020 With Exelixis?
This pharma stock can look forward to a year with more readouts, potential approvals, and new clinical assets providing value in the oncology space.